ASAllan D. Sniderman

Allan D. Sniderman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Allan D. Sniderman has a total of 171 co-authors. Here are the top co-authors by number of shared publications:

  • George Thanassoulis

    Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, Royal Victoria Hospital, McGill University Health Centre, Montreal, Canada (Cole, Dufresne, Thanassoulis, and Sniderman)

    28 shared publications
  • Curt D. Furberg

    Public Health Sciences Wake Forest University Winston-Salem NC

    13 shared publications
  • Michael Pencina

    Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, Department of Medicine, McGill University Health Centre, 1001 Decarie Blvd, Montreal, Quebec H4A 3J1, Canada; Duke University School of Medicine, Biostatistics and Bioinformatics, DCRI, 2424 Erwin Road, Durham, NC 27705, USA

    12 shared publications
  • George Thanassoulis

    McGill University

    10 shared publications
  • Ken Williams

    KenAnCo Biostatistics, San Antonio, Texas

    10 shared publications
  • Patrick Couture

    Centre Nutrition, santé et société (NUTRISS), Institut sur la nutrition et les aliments fonctionnels (INAF), Université Laval, Québec, QC G1V 0A6, Canada

    9 shared publications

Latest Publications

  • HDL and apoB: physiological and pathophysiological intersections and interactions

    by Allan D. Sniderman

    Purpose of review: To reexamine why high-density lipoprotein cholesterol (HDL-C) has been widely dismissed as a causal factor for atherosclerotic cardiovascular disease (ASCVD) and to point to evidence of interactions between HDL particles and apolipoprotein B (apoB) that may modify risk. Recent findings: Notwithstanding the epidemiological evidence of a potent inverse relation between HDL-C and ASCVD risk, neither Mendelian randomization analyses nor randomized clinical trials with multiple classes of agents have confirmed a causal connection. However, this assumes HDL-C is a valid physiological entity, which it is not. HDL-C is a construct, the arithmetic sum of the cholesterol within the HDL particles. Cholesterol is only one constituent of these particles and, at most, cholesterol is a physiological product whereas other elements in the particle would be the physiological actors. HDL-C is only a surrogate for HDL particles. The relation of HDL-C to ASCVD risk persists after triglycerides are accounted for. Evidence of a potentially positive clinical interaction between HDL-C and apoB will be identified. Summary: HDL-C is a useful clinical and research tool but not a biological entity. Any putative biological property of HDL must relate to a specific class or classes of HDL particles. However, HDL-C remains a valid tool to assess the risk of ASCVD

  • Open Access

    Does the evidence support the ACC/AHA multisociety recommendation to measure apoB only after LDL-C and non–HDL-C are at target?

    by Justine Cole, Line Dufresne, Peter P. Toth, Michel Langlois, George Thanassoulis, Allan D. Sniderman


  • Open Access

    Cholesterol homeostasis in the hepatocyte

    by Justine Cole, Iana Pencina, Robert Kiss, Rafael Zubiran, Allan D. Sniderman

  • Open Access

    Is the Commitment to LDL-C Eternal?

    by Allan D. Sniderman

    Low-density lipoprotein cholesterol (LDL-C) has been the cornerstone of cardiovascular risk assessment and therapy since 1988. Every guideline group and consensus report has repeated and reinforced this commitment. Yet in 2019, the European Society of Cardiology/European Atherosclerosis Society Lipid Guidelines declared that (1) apolipoprotein B (apoB) was a more accurate marker of cardiovascular risk than LDL-C or non-high-density lipoprotein cholesterol (HDL-C); (2) that apoB was a more accurate marker of the adequacy of therapy to lower cardiovascular risk than LDL-C or non-HDL-C; (3) that apoB was essential to diagnose disorders such as type III hyperlipoproteinemia and familial combined hyperlipidemia; and (4) that apoB could be measured more accurately, particularly at low concentrations, than LDL-C or non-HDL-C. Yet LDL-C remained the dominant metric for clinical care in their recommendations, and in the 7 years since, there has been minimal organized teaching about apoB in either Europe or the United States. In 2026, the American College of Cardiology/American Heart Association/Multisociety dyslipidemia guideline followed virtually the same course. Based on the evidence, apoB was ranked above both LDL-C and HDL-C for assessment of risk and the effectiveness of therapy. However, the actual recommendations ranked apoB below both and, as written, make it unlikely that apoB will be commonly used in clinical care for either purpose.How can this be, and what can we learn? LDL-C transformed cardiovascular care, and the effort to teach patients and doctors about LDL-C is unprecedented. How much of the resistance to apoB is the concern that it is too late to change? How many who write the guidelines have routinely used apoB in their clinical care? I believe that an unreasonable commitment to continuity of message and too closed a process of deliberation and review have produced this unprecedented contradiction between the guideline recommendations and the evidence. This article outlines the critical need to re-evaluate the framework and procedural standards governing our current guidelines.

  • Open Access

    APOB to Estimated APOB Ratio for Screening for the APOE2 Genotype

    by Claire Auger, Maureen Sampson, Rafael Zubiran, Justine Cole, Anna Wolska, James D Otvos, Allan D Sniderman, Alan T Remaley

    Background: Familial dysbetalipoproteinemia (FDB) is a genetic lipoprotein disorder that can develop in patients homozygous for the apolipoprotein 2 (APOE2) genotype (APOE ɛ2/ɛ2). It is associated with decreased clearance of remnant lipoproteins and increased atherosclerotic cardiovascular disease (ASCVD) risk disproportionate to low-density lipoprotein-cholesterol level. A goal of this study was to develop a screening test for the ɛ2/ɛ2 genotype based on routinely available lipid tests and to determine those at most risk for ASCVD. Materials and Methods: After assembly of a primary prevention cohort from the UK Biobank (n = 298 249), gene array and exome data were utilized to classify patients as being ɛ2/ɛ2 genotype positive or negative. Lipid profiles and apolipoprotein B‎ (APOB) levels were extracted and the number of ASCVD events was tabulated during a 15-year follow-up period. Results: Using a newly developed equation for estimating APOB (eAPOB) with lipid panel test results, the ratio of measured APOB to eAPOB was better than any other individual lipid test or ratio for identifying patients with the ɛ2/ɛ2 genotype [area under the curve‎ (AUC): APOB/eAPOB: 0.990 (0.986–0.994), nonhigh-density lipoprotein cholesterol/APOB: 0.961 (0.952–0.970), APOB: 0.955 (0.949–0.961), very low-density lipoproteins/triglycerides: 0.788 (0.771–0.804)]. Most ɛ2/ɛ2 patients could be identified with the APOB/eAPOB ratio regardless of their FDB phenotype status. The PCE or PREVENT risk equations were the most accurate method for identifying higher risk patients [AUC: PREVENT: 0.690 (0.637–0.742), PCE: 0.697 (0.645–0.749)]. Conclusion: The APOB/eAPOB ratio can be used to accurately identify the ɛ2/ɛ2 genotype and conventional risk equations are the best method for determining those at risk for ASCVD.

  • Open Access

    Interplay of HDL cholesterol and apoB and the risk of incident atherosclerotic cardiovascular disease in UK Biobank

    by Allan Sniderman, Karol Pencina, George Thanassoulis, Line Dufresne, Michael Pencina

    Aims: Apolipoprotein B (apoB) is the most accurate causal lipid factor associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). While high HDL cholesterol has been considered protective, HDL-C–raising therapies have not shown benefit. Objective: To assess whether HDL-C provides independent information from apoB and whether HDL-C modifies the effect of apoB on ASCVD risk. Methods and results: 293 872 UK Biobank participants aged 37–73, free of CVD, not on lipid-lowering medication, and with complete standard risk factor data were followed for 10 years for incident ASCVD. Cox proportional hazard models, adjusted for standard risk factors, including log-triglycerides, used apoB and HDL-C residuals (regressed on each other) as primary exposures. Interaction between apoB and HDL-C was tested separately. When HDL-C residual was added to a model with apoB, both were significant: hazard ratios (HRs) per 1 SD were 1.16 (95% confidence interval, CI: 1.15–1.18; P < 0.001) for apoB and 0.85 (95% CI: 0.84–0.87; P < 0.001) for HDL-C residual. Similarly, adding apoB residual to a model with HDL-C yielded HRs of 1.14 (95% CI: 1.12–1.16; P < 0.001) for apoB residual and 0.84 (95% CI: 0.82–0.85; P < 0.001) for HDL-C. The apoB–HDL-C interaction was significant: HR 0.95 (95% CI: 0.93–0.96; P < 0.001), consistent across sexes. Conclusion: High HDL-C is associated with lower ASCVD risk, independent of apoB, and it attenuates the effect of high apoB on ASCVD risk. These findings suggest HDL-C’s role in primary ASCVD prevention warrants re-evaluation. However, findings from an observational study, such as this, do not establish causation.


  • HDL and coronary artery disease

    by Michael Pencina, Allan Sniderman

  • Open Access

    ApoA-1 versus HDL-C as markers of cardiovascular risk

    by Selin Bilgic, Karol Pencina, Michael Pencina, Line Dufresne, George Thanassoulis, Allan Sniderman


  • The PROACT Study and Improving Prevention of ASCVD

    by Allan Sniderman